19 November 2026

London Life Sciences Week 2026 day three: investors, founders and capital

Martin Turner, Director of Policy and External Affairs, BIA speaking at the International Investor Summit

Martin Turner, Director of Policy and External Affairs, BIA speaking at the International Investor Summit

Breakfast with French and UK life sciences ecosystems

The day began at Victoria House with a networking breakfast for entrepreneurs, pharma executives and C-level leaders from life sciences companies, and investors, from the French and UK ecosystems. France Biotech, the French biotech, medtech and digital health trade association, and the BIA organised it in partnership with Foreign Trade Advisors for France, to explore partnerships, collaborations and investment between the two countries. Jane Wall, our Managing Director, welcomed guests alongside Frédéric Girard, President of France Biotech.

The conversation moves to Paris soon, as Jane will be at TechBio Europe at Future4Care on 30 November.

Innovate or stall: leading change in UK health

Across town, Dr Emma Lawrence, our Head of Data Tech Policy and Public Affairs, went to a breakfast discussion at the Academy of Medical Sciences on leading change in UK health. The panel was Rosalind Campion, Dame Caroline Clarke, Hilary Evans-Newton CBE of Alzheimer’s Research UK and Melanie Ivarsson OBE of the Health Data Research Service. They asked whether the system should be reformed bit by bit or rebuilt from the ground up. Emma reports that the panel agreed change depends on people, and that bringing stakeholders along matters whichever route is taken. They also spoke about getting innovation to patients faster and more consistently, and about learning from the Nordic countries on health data. The session ended on an optimistic note about the UK’s position in life sciences.

Backing the next generation of founders

The New frontiers showcase at 180 Studios began with an early-stage investor breakfast at 8am. An investor panel followed, with Katie Lockwood of TwinPath Ventures, Oliver Sexton of Future Planet Capital and Hayley Cross of Mishcon Plus, moderated by Sunil Shah of o2h Ventures. Ten early-stage companies pitched, in pre-seed and seed and then seed and Series A sessions. Toby Richardson of Johnson & Johnson and Jeannie Rojas of GSK gave the pharma view.

In the afternoon, 'From spinout to scale: the decisions nobody prepares you for' put the founder experience at the centre. Professor Edward Tate shared what building companies around academic research involves, and a founder challenge followed with Mishcon de Reya, Novartis and Cancer Research Horizons. A well-matched investor brings a development perspective as well as capital, and for a founder the value is in testing how you explain your science and what you need to achieve next.

The BIA International Investor Summit

At 60 Great Queen Street, the International Investor Summit returned for a second year, delivered with the UK Government and open to active life sciences investors. Martin Turner, our Director of Policy and External Affairs, and Robbie McLaren, Partner and Vice Chair of Healthcare and Life Sciences at Latham & Watkins, welcomed guests.

Chris McDonald MP, Minister for Science, Innovation and Investment, gave the ministerial address and restated the Government’s ambition for the UK to be the leading life sciences economy in Europe by 2030.

Leandros Kalisperas, Chief Investment Officer at the British Business Bank, spoke on the bank’s role in the UK life sciences ecosystem and argued that the UK is strong at innovation and needs more capital behind it, including from pension funds.

A panel asked what makes the UK a great place for life science investment, with Katherine Andersen of HSBC Innovation Banking, Kate Bingham of SV Health Investors, Avi Spier of Novartis, Dan Mahony, the Office for Life Sciences’ Life Science Envoy, and Otello Stampacchia of Omega Funds.

Panellists pointed to the regulator, the connected sector and the UK’s health data as strengths, and to the time it takes to open clinical trial sites as something to fix. Chris Molloy closed the afternoon and told the room: “Please, bring your money here. We’ll spend it well.”

The BIA view: the UK has led Europe for biotech venture capital in every quarter of 2026 so far. It took 30% of European biotech venture financing in 2025, according to our 2025 report, 57% in the first quarter of 2026, and a record £2.05 billion, 61% of the European total, in the second quarter. Our analysis shows UK biotechs have raised £3.3 billion of (venture capital or equity finance) so far this year, to 9 November. We expect 2026 to be the best year since 2021.

CEOs and investors at Victoria House

At 4pm, the Fourth Biotech CEO & Investor Reception opened at Victoria House with a live recording of the BioCentury This Week podcast, followed by networking for C-level executives and investors. We hosted it with BioCentury, Pioneer and Precision BioSearch.

You can also read our six key messages for London Life Sciences Week.

Thank you to everyone who joined us this week. Chris Molloy's blog on Monday will look back on the week as a whole.